They have over $500 million in cash and $1 billion in revenue (most of it from Daptomyacin).
Their Market Cap is about $5 billion,... with about 75 million shares outstanding, trading at $66.51,... with a high of over $80 this year.
I can see them taking an interest in purchasing B (ABSSSI) from CTIX. They have the cash and also the distribution network in place for serious Anti-Biotic medicines.
They are also situated in Lexington, Massachusetts... not too far from us.
They might also be interested in the drugs CTIX is doing INVIVO testing for at that Texas University.
In a thigh burden study of a multi-drug resistant strain of Klebsiella pneumoniae in a mouse model, Cellceutix’s defensin mimetic compound CTIX1278, was efficacious as compared to a carbapenem antibiotic that is widely used as a last line of defense against drug-resistant, Gram-negative bacteria, including Klebsiella pneumoniae. A second study is now being conducted at multiple dosing levels with various infusion parameters with the goal of increasing efficacy and further defining a treatment protocol for the compound.
Gov, here's the sentence talking about the 1 Billion $:
"Apart from announcing its earnings results, Cubist Pharma reiterated the guidance for 2014 provided by it while releasing its fourth quarter and full year 2013 results in January. The company still expects revenues in the range of $1.19–$1.275 billion. The Zacks Consensus Estimate of $1.0 billion is below the guided range. Net U.S. sales of Cubicin are still expected in the range of $0.97–$1.02 billion. All other product revenues are still projected in the range of $205–$235 million. Service and other revenues are still expected in the range of $15–$20 million. Gross margin (on an adjusted basis) is still expected in the range of 77%–78%."
News 
Market Data 
Discover 
